Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
Reversible acetylation is mediated by histone deacetylase (HDAC), which is involved in regulating a broad repertoire of physiological processes, many of which are under aberrant control in tumor cells. Inhibition of HDAC activity prompts tumor cells to enter apoptosis; therefore, the utility of HDAC...
Những tác giả chính: | , |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
2008
|